Chih Ming Chen
Director Ejecutivo en TWI PHARMACEUTICALS INC .
Perfil
Chih Ming Chen is the founder of TWi Pharmaceuticals, Inc. (founded in 1997) and TWi Biotechnology, Inc. (founded in 2010).
He holds the title of Chairman & Chief Executive Officer at TWi Pharmaceuticals, Inc. and Chairman at TWi Biotechnology, Inc. Dr. Chen is also the founder of Allgenesis Biotherapeutics, Inc. Dr. Chen's current jobs include Director positions at TWi Pharmaceuticals Holding, Inc., Eldridge Capital Group Ltd., and Delightful Cheers Ltd.
Dr. Chen's former job was as Chairman of Jiachen International Pharmaceutical Co., Ltd.
Dr. Chen's education includes a doctorate degree from The Ohio State University (conferred in 1981), an undergraduate degree from National Taiwan University (conferred in 1974), and a graduate degree from National Taiwan University (conferred in 1976).
Cargos activos de Chih Ming Chen
| Empresas | Cargo | Inicio |
|---|---|---|
| TWI PHARMACEUTICALS INC | Director Ejecutivo | 01/12/1997 |
TWi Pharmaceuticals Holding, Inc.
 TWi Pharmaceuticals Holding, Inc. Pharmaceuticals: MajorHealth Technology TWi Pharmaceuticals Holding, Inc. provides pharmaceutical services. | Director/Miembro de la Junta | - |
| Delightful Cheers Ltd. | Director/Miembro de la Junta | - |
| Eldridge Capital Group Ltd. | Director/Miembro de la Junta | - |
Allgenesis Biotherapeutics, Inc.
 Allgenesis Biotherapeutics, Inc. BiotechnologyHealth Technology Allgenesis Biotherapeutics, Inc. is a Taiwanese clinical-stage biopharmaceutical company focused on researching and developing novel medicines for the treatment of eye diseases. The private company is based in Taipei, Taiwan. The company's current pipeline includes potential blockbuster drugs such as ag-73305 for the treatment of DME, NAMD, and other retinal diseases, as well as ag-80308 for dry eye disease. The company was founded by Chih Lung Shen and Chih Ming Chen. Madhu Cherukury has been the CEO of the company since 2014. | Fundador | - |
Antiguos cargos conocidos de Chih Ming Chen.
| Empresas | Cargo | Fin |
|---|---|---|
Jiachen International Pharmaceutical Co., Ltd.
 Jiachen International Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Jiachen International Pharmaceutical Co., Ltd. engages in the investment, biotechnology service and management consulting industries. The company was founded on February 15, 2019 and is headquartered in Taipei, Taiwan. | Presidente | - |
| TWI BIOTECHNOLOGY, INC. | Fundador | - |
Formación de Chih Ming Chen.
| The Ohio State University | Doctorate Degree |
| National Taiwan University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| TWI BIOTECHNOLOGY, INC. | Health Technology |
| Empresas privadas | 6 |
|---|---|
TWi Pharmaceuticals, Inc.
 TWi Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology TWi Pharmaceuticals, Inc. operates as a technology-based special pharmaceutical company. The firm engages in the development and commercialization of high barrier generics drugs. Its products include donepezil hydrochloride tablets, megestrol acetate oral suspension, hydroquinone cream, guanfacine extended-release tablets and nifedipine extended-release tablets. The company was founded by Chih Ming Chen on December 1, 1997 and is headquartered in Taipei, Taiwan. | Health Technology |
TWi Pharmaceuticals Holding, Inc.
TWi Pharmaceuticals Holding, Inc. Pharmaceuticals: MajorHealth Technology TWi Pharmaceuticals Holding, Inc. provides pharmaceutical services. | Health Technology |
| Eldridge Capital Group Ltd. | |
Allgenesis Biotherapeutics, Inc.
Allgenesis Biotherapeutics, Inc. BiotechnologyHealth Technology Allgenesis Biotherapeutics, Inc. is a Taiwanese clinical-stage biopharmaceutical company focused on researching and developing novel medicines for the treatment of eye diseases. The private company is based in Taipei, Taiwan. The company's current pipeline includes potential blockbuster drugs such as ag-73305 for the treatment of DME, NAMD, and other retinal diseases, as well as ag-80308 for dry eye disease. The company was founded by Chih Lung Shen and Chih Ming Chen. Madhu Cherukury has been the CEO of the company since 2014. | Health Technology |
Jiachen International Pharmaceutical Co., Ltd.
Jiachen International Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Jiachen International Pharmaceutical Co., Ltd. engages in the investment, biotechnology service and management consulting industries. The company was founded on February 15, 2019 and is headquartered in Taipei, Taiwan. | Health Technology |
| Delightful Cheers Ltd. |
- Bolsa de valores
- Insiders
- Chih Ming Chen
